

# Compositions and Methods using RNA Splicing Modulation to Selectively Impair Leukemic Cancer Stem Cells

Tech ID: 27067 / UC Case 2016-033-0

## BACKGROUND

The advancing age of the US population and increasing exposure to chemotherapy (for other malignancies) has resulted in increased rates of myelodysplastic syndrome (MDS). Following on the heels of MDS is progression to therapy-resistant acute myeloid leukemia (AML), which is predicted to rise significantly over the next few decades. The heterogeneity of molecular abnormalities in therapy-resistant secondary acute myeloid leukemia (sAML) combined with a paucity of effective treatment options has resulted in high relapse-related mortality rates. In addition to approved therapies, many experimental agents also target epigenetic regulators of gene expression in clinical trials for sAML. However, most of these agents fail to improve patient survival, suggesting that epigenetic modifier therapies may reduce leukemic burden but may not effectively target a subpopulation of therapy-resistant leukemia stem cells that drive relapse. Hence, there is a critical need for developing clinical candidates with different modes of action. Recent studies implicate the spliceosome as a therapeutic vulnerability in solid tumors.

## TECHNOLOGY DESCRIPTION

Researchers from UC San Diego used comparative splice isoform profiling of FACS-purified hematopoietic progenitors and whole transcriptome analyses, to identify unique splicing signatures that distinguishes normal human HSC and progenitor cell aging from AML and MDS progenitors. The diagnostic potential is validated by confirmation that a novel pharmacological spliceosome modulatory drug (see [FD-895](#) and [17s-FD-895](#)) disrupted AML leukemia stem cell (LSC) maintenance. Furthermore, normal versus malignant aging splice isoform switching signatures may be exploited in companion diagnostics to evaluate the efficacy of splicing modulators or other LSC-targeted agents.

## APPLICATIONS

AML stem cell signatures may enable diagnostic and prognostic assessment of disease risk, patient stratification, and response to therapy. In addition, this technology enables the identification of splice modulating drugs (as validated with [FD-895](#) and [17s-FD-895](#)) as that may disrupt AML leukemia stem cell (LSC) maintenance by promoting intron retention and altering splicing of AML-associated/pro-survival transcripts.

## ADVANTAGES

- ▶ Splice isoform signatures distinguish normal and malignant progenitor cell aging
- ▶ Pro-survival splice isoform switching is a feature of secondary AML LSC
- ▶ Splice isoform biomarkers provide diagnostic and therapeutic targets for AML
- ▶ Spliceosome modulators impair AML LSC maintenance in humanized pre-clinical models

## STATE OF DEVELOPMENT

## CONTACT

University of California, San Diego  
Office of Innovation and  
Commercialization  
[innovation@ucsd.edu](mailto:innovation@ucsd.edu)  
tel: 858.534.5815.



## OTHER INFORMATION

### KEYWORDS

AML, MDS, sAML, HSC, LSC, leukemia, spliceosome, transcriptome analyses

### CATEGORIZED AS

- ▶ **Medical**
  - ▶ Disease: Cancer
  - ▶ Research Tools
  - ▶ Therapeutics
- ▶ **Research Tools**
  - ▶ Other

### RELATED CASES

2016-033-0, 2012-262-0

Pre-clinical studies identified a predictive splice isoform biomarker for sAML and the anti-tumor activity of novel compositions of matter were demonstrated in vitro and in vivo (in a mouse model of AML). Splice modulatory compounds were validated toward this MOA by using a splicing reporter and PCR assays.

## INTELLECTUAL PROPERTY INFO

Worldwide rights available for pending patents available under confidentiality. A published, US patent on composition of matter is described at "[Synthetic Anticancer Polyketide Compounds](#)".

## PATENT STATUS

Country	Type	Number	Dated	Case
United States Of America	Issued Patent	10,675,267	06/09/2020	2016-033
United States Of America	Issued Patent	9,604,973	03/28/2017	2012-262
Patent Cooperation Treaty	Published Application	2017053887	03/30/2017	2016-033

## RELATED MATERIALS

- ▶ Crews LA1, Balaian L2, Delos Santos NP2, Leu HS2, Court AC2, Lazzari E2, Sadarangani A2, Zipeto MA2, La Clair JJ3, Villa R3, Kulidjian A4, Storb R5, Morris SR6, Ball ED7, Burkart MD3, Jamieson CH8. RNA Splicing Modulation Selectively Impairs Leukemia Stem Cell Maintenance in Secondary Human AML. *Cell Stem Cell*(16) 30250-30258 (2016) - 08/25/2016
- ▶ Kashyap, M.K., et al. Targeting the spliceosome in chronic lymphocytic leukemia with the macrolides FD-895 and pladienolide B. *Haematologica* (2015). - 07/01/2015
- ▶ Adamia, S., et al. A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targets. *Clin Cancer Res* 20, 1135-1145 (2014). - 03/01/2014
- ▶ Villa R, Kashyap MK, Kumar D, Kipps TJ, Castro JE, La Clair JJ, Burkart MD. Stabilized cyclopropane analogs of the splicing inhibitor FD-895. *J Med Chem* 56, 6576-6582 (2013). - 09/12/2013
- ▶ Mandel, A.L., Jones, B.D., La Clair, J.J. & Burkart, M.D. A synthetic entry to pladienolide B and FD-895. *Bioorg Med Chem Lett* 17, 5159-5164 (2007). - 09/15/2007

## RELATED TECHNOLOGIES

- ▶ [Synthetic Anticancer Polyketide Compounds](#)

University of California, San Diego  
Office of Innovation and Commercialization  
9500 Gilman Drive, MC 0910, ,  
La Jolla, CA 92093-0910

Tel: 858.534.5815  
innovation@ucsd.edu  
<https://innovation.ucsd.edu>  
Fax: 858.534.7345

© 2016 - 2020, The  
Regents of the University of  
California  
[Terms of use](#)  
[Privacy Notice](#)